T2 Biosystems, Inc. (NASDAQ:TTOO) Short Interest Update

T2 Biosystems, Inc. (NASDAQ:TTOOGet Free Report) was the target of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 624,900 shares, a decrease of 28.6% from the November 30th total of 875,200 shares. Currently, 6.7% of the shares of the company are short sold. Based on an average trading volume of 782,300 shares, the short-interest ratio is currently 0.8 days.

T2 Biosystems Stock Performance

Shares of NASDAQ TTOO traded up $0.02 during midday trading on Friday, reaching $0.43. 795,770 shares of the company were exchanged, compared to its average volume of 404,656. The stock’s 50-day moving average price is $0.62 and its 200-day moving average price is $2.62. T2 Biosystems has a one year low of $0.31 and a one year high of $8.38.

Wall Street Analyst Weigh In

Separately, StockNews.com started coverage on T2 Biosystems in a research report on Saturday. They issued a “sell” rating on the stock.

Read Our Latest Research Report on TTOO

Institutional Investors Weigh In On T2 Biosystems

An institutional investor recently bought a new position in T2 Biosystems stock. Armistice Capital LLC bought a new stake in shares of T2 Biosystems, Inc. (NASDAQ:TTOOFree Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,658,000 shares of the medical equipment provider’s stock, valued at approximately $8,854,000. Armistice Capital LLC owned 9.49% of T2 Biosystems as of its most recent filing with the Securities and Exchange Commission. 23.18% of the stock is owned by hedge funds and other institutional investors.

T2 Biosystems Company Profile

(Get Free Report)

T2 Biosystems, Inc, an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.

Recommended Stories

Receive News & Ratings for T2 Biosystems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for T2 Biosystems and related companies with MarketBeat.com's FREE daily email newsletter.